American Society of Cataract and Refractive Surgery (ASCRS)’s Post

Screening failure for transcatheter tricuspid valve replacement (TTVR) is high at 74%, mainly related to large tricuspid annular diameter, but tricuspid regurgitation reduction is superior with TTVR compared with tricuspid transcatheter edge-to-edge repair and optimal medical therapy, a new registry analysis shows. Read more on #CRTonline. https://ow.ly/tmv950QIikZ

Curious to learn more about our First-in-Human Study of BRB-002? Check out our press release here: https://lnkd.in/euhPue-g #BitterrootBio #BRB002 #FirstinHuman #heartdisease #cardiovascular #drugdevelopment 

Attending ACC 2024? Seeking conference coverage support in the cardiometabolic realm? CVrg is all set to analyze the latest data, especially in HF, DYS/ATH, and other CVM indications. Curious about our year-round conference plans? Reach out to Brooke Blackwelder for details into how CVrg can support your needs! Let's navigate the cardiometabolic landscape together! #ACC24 #Cardiometabolic #cardiovascular #pharmaCI #competitveintelligence #pipelinestrategy

Dr. Shin and his group recently published a retrospective, single-center study comparing therapeutic efficacy and technical outcomes between conventional fixed electrodes and adjustable electrodes in the RFA of benign thyroid nodules. After evaluating 182 nodules on 173 patients, they concluded that adjustable electrodes demonstrated better technical outcomes than fixed electrodes in terms of RFA time, ablated volume/energy, and ablated volume/time. Read: https://lnkd.in/esetzat8  Learn more about STARmed technologies: STARmed-America.com #STARmedRFA #ThyroidNoduleTreatment

Simply Bigger. The VASCADE MVP® XL Venous Vascular Closure System offers a 58% increase in collagen and 9% increase in disc size compared to VASCADE MVP®. Discover how VASCADE MVP® XL can make a difference for you and your patients today! https://hubs.ly/Q02LKTmP0 #SimplyBigger #ePeeps #Afib #VASCADEMVPXL

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/4aryVhk Risk Info: https://bit.ly/49AjEJz TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Check out this insightful editorial by Tanaka et al on the value of #Clotpro and its unique #TPA-test. The Clot-Pro® TPA test helps in dose-response assessment to TXA, making it a useful tool in maintaining therapeutic TXA concentrations during postpartum hemorrhage. The findings are a testament to the clinical utility of this viscoelastic coagulation test. Read more: https://lnkd.in/gjRbyxey.

The #SMARTtrial reveals that Evolut™ #TAVR delivers 5x less bioprosthetic valve dysfunction (BVD) in women vs. SAPIEN™* platform at 1 year.¹ Explore the evidence: https://bit.ly/3QClH9n Risk Info: https://bit.ly/3WyhSWv TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024

Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg http://ow.ly/XzxC105z0m8

Because women typically have smaller annuli than men, they require a valve that provides the largest area of blood flow to maximize valve performance. Valve choice makes a difference. The Evolut™ #TAVR system has a unique design that enables greater blood flow and improved outcomes compared to SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/442CAja #AorticStenosis #SMARTtrial Risk Info: https://bit.ly/4cSqvB4 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.